Time course of the defective α-cell response to hypoglycemia in diabetic BB rats

Abstract

Although it is understood that patients with insulin-dependent diabetes mellitus (IDDM) lose the ability to release glucagon during a hypoglycemic challenge, the relationship of this defect to the disease onset and loss of β-cell function is not well defined. To address this issue, we measured the counterregulatory response in three groups of BB/wor rats during sequential 90-minute euglycemic (7 mmol/L) and hypoglycemic (3 mmol/L) insulin clamps (180 pmol/kg · min). Group 1 (n = 8) consisted of nondiabetic BB rats (aged 84 ± 3 days), and groups 2 and 3 were rats studied 1 day (n = 7) or 7 days (n = 6) after diabetes onset. Plasma glucagon concentrations were similar in all groups during euglycemia (244 ± 47 ng/L for nondiabetic, 308 ± 38 for 1 day of diabetes, and 277 ± 30 for 7 days of diabetes). Moreover, after 1 day of diabetes, the increase in plasma glucagon during hypoglycemia was similar to that seen in controls (to 581 ± 94 and 650 ± 118 ng/L, respectively) even though insulin production by the pancreas was virtually absent. However, after 7 days of diabetes, plasma glucagon only increased to 339 ± 59 ng/L during hypoglycemia ( P = nonsignificant v basal), despite normal pancreatic glucagon content (11.5 ± 1.2 v 10.8 ± 0.6 μ/g in nondiabetic controls). In conclusion, the hypoglycemia-associated defect in glucagon release occurs early in the course of diabetes in BB rats and is not associated with decreased baseline plasma or pancreatic glucagon levels. This impairtment, although not immediately linked to the decrease in pancreatic insulin content, occurs soon afterward, implying that the two events are related.